ClinicalTrialsFinder

HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis Clinical Trials in Beijing, Beijing Municipality

1 recruitingBeijing, Beijing Municipality, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences184 enrolled1 locationNCT07203729